Combination of Ibrutinib and As2O3 in the Treatment of CLL

Clinical trial NCT02757040 · UNKNOWN

Trial details

NCT number: NCT02757040
Sponsor: Peking University People's Hospital
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Leukemia, Lymphocytic, Chronic, B-Cell

Start date: 2016-12-01
Primary completion: 2017-12-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.